z-logo
open-access-imgOpen Access
2020–2021 Drug Updates in Solid Tumors
Author(s) -
Christine Cambareri
Publication year - 2022
Publication title -
journal of the advanced practitioner in oncology
Language(s) - English
Resource type - Journals
eISSN - 2150-0886
pISSN - 2150-0878
DOI - 10.6004/jadpro.2022.13.3.19
Subject(s) - medicine , drug , adverse effect , drug approval , intensive care medicine , medical physics , pharmacology
During JADPRO Live Virtual 2021, Christine Cambareri, PharmD, BCPS, BCOP, CSP, briefed advanced practitioners on drugs and biologics that were approved for the treatment of solid tumors from late 2020 to late 2021, including their adverse event profiles. The trend of more oral dosage forms and the significant number of checkpoint inhibitors approved points towards changing treatment paradigms in the field.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here